Excellergy

Executive Summary

Excellergy is a clinical-stage biotechnology company pioneering a new class of allergy therapeutics called Effector Cell Response Inhibitors (ECRIs). Based in San Francisco, the company is developing trifunctional biologics designed to rapidly and completely control allergic responses by disarming immune effector cells, neutralizing circulating IgE, and downregulating IgE receptors. With its lead candidate advancing in Phase 3 clinical trials, Excellergy addresses a significant unmet need in allergy treatment, offering potential for improved efficacy and convenience over existing therapies. The company's innovative mechanism targets the root cause of allergic reactions, positioning it as a potential game-changer in the allergy market.

Upcoming Catalysts (preview)

• Q1 2027Phase 3 Pivotal Trial Top-Line Results60% success
• Q3 2027FDA Submission for Biologics License Application (BLA)50% success
• Q4 2026Strategic Partnership or Licensing Deal40% success